ArticleMovement disorders clinical practice2025
Serum Myeloperoxidase Activity Is Associated with Hoehn-Yahr Staging and Striatal Dopamine-Transporter Binding in Parkinson's Disease.
Article in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Pathophysiological Model of Parkinson's Disease Based on Microvascular Flow Disturbance and Leukocyte-Mediated Oxidative Injury in Critical Pigmented Neuronal Niches.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe blood concentration of myeloperoxidase (MPO) is related to the severity of many age-related inflammatory diseases. However, it is unknown whether enzyme activity in the blood provides information on the degree of functional disability of Parkinson's disease (PD), a multifactorial disease in which aging and inflammation play an important role.
objectiveThe aim of the study was to discern the relationship between MPO activity in blood serum and the clinical characteristics of PD, assessed by disease rating scales and neuroimaging methods.
methodsThis cross-sectional study included 217 participants (114 patients and 103 controls). Disease rating scales included the Hoehn-Yahr scale, the International Parkinson and Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale motor section (MDS-UPDRS), and the Schwab-England Daily Living scale. The neuroimaging study was based on dopamine transporter single-photon emission computed tomography (DAT-SPECT) and specific binding ratio (SBR) quantification of
resultsThe findings revealed that serum MPO activity significantly increased in PD patients (P < 0.0001). MPO activity correlated with the degree of clinical impairment measured with rating scales and with striatal DAT availability assessed with DAT-SPECT. Multivariate linear regression, correcting for all confounding factors, shows that the Hoehn-Yahr staging (P = 0.004) and left striatum specific binding ratio (SBR) (P < 0.05) are predictors of serum MPO activity, along with dysthyroidism and statins use (P < 0.005). MPO activity cutoff greater than 40.350 U/L differentiated patients from controls with good accuracy (78.9%).
conclusionsIn PD, MPO activity in blood serum is associated with the stage of functional disability, apart from dysthyroidism and use of statins, assessed with the Hoehn-Yahr scale and striatal DAT binding.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.